DuraGraft Vascular Conduit Preservation Solution in Patients Undergoing Coronary Artery Bypass Grafting: Rationale and Design of a Within-patient Randomised Multicentre Trial

Overview

Journal Open Heart

Publisher BMJ Publishing Group

Specialty Cardiology & Vascular Diseases

Date 2018 Apr 24

PMID 29682294

Citations 6

Authors

Walid Ben Ali

Pierre Voisine

Peter Skov Olsen

Hugues Jeanmart

Nicolas Noiseux

Tracy Goeken

Vilas Satishchandran

Filippo Cademartiri

Garry Cutter

Dave Veerasingam

Craig Brown

Maximilian Y Emmert

Louis P Perrault

Affiliations

Soon will be listed here.

Abstract

Introduction: Saphenous vein grafts (SVGs) remain the most often used conduits in coronary artery bypass grafting (CABG). However, they are prone to vein graft disease (VGD) during follow-up, which may compromise clinical outcomes. Injury to the SVG endothelium during harvesting and storage promotes neointimal hyperplasia that can advance to atherosclerosis characterised by SVG failure. This trial investigates the potential benefit of DuraGraft, a novel, one-time intraoperative graft treatment developed to efficiently protect the structural and functional integrity of the vascular endothelium, on the development and progression of VGD in CABG patients.

Methods And Analysis: This ongoing prospective randomised, double-blinded multicentre trial (NCT02272582/NCT02774824) includes patients undergoing isolated CABG requiring at least two SVGs. It compares the impact of DuraGraft, a novel treatment against VGD versus the (SOC; heparinised saline) using a within-patient randomisation (with one SVG treated with DuraGraft and the other treated with SOC). Besides clinical assessments, patients undergo longitudinal 64-slice or better multidetector CT (MDCT) angiography of paired grafts (within each patient) at 4-6 weeks, 3 months and 12 months. Primary endpoints will be the magnitude of change in mean wall thickness and lumen diameter (stenosis) of paired grafts, at 3 and 12 months, respectively. Besides the evaluation of overall safety, longitudinal assessment of each graft (secondary endpoint) is performed in order to obtain insight into graft behaviour after CABG. Enrolment of 119 patients was successfully completed, and analysis of MDCT angiography follow-up is ongoing with the completed analysis becoming available by end of first quarter of 2018.

Ethics And Dissemination: The regional ethics committees have approved the trial. Results will be submitted for publication.

Clinical Trial Identifier: NCT02272582 and NCT02774824.

Citing Articles

Outcomes after surgical revascularization in diabetic patients.

Misfeld M, Sandner S, Caliskan E, Boning A, Aramendi J, Salzberg S Interdiscip Cardiovasc Thorac Surg. 2024; 38(2).

PMID: 38218725 PMC: 10850843. DOI: 10.1093/icvts/ivae014.

The percutaneous coronary angioplasty gets better, but the surgical coronary artery bypass does not stay behind.

De Paulis R, Folino G, Scaffa R Eur Heart J Suppl. 2022; 24(Suppl I):I81-I83.

PMID: 36380805 PMC: 9653154. DOI: 10.1093/eurheartjsupp/suac077.

Efficacy of Intraoperative Vein Graft Storage Solutions in Preserving Endothelial Cell Integrity during Coronary Artery Bypass Surgery.

Toto F, Torre T, Turchetto L, Cicero V, Soncin S, Klersy C J Clin Med. 2022; 11(4).

PMID: 35207364 PMC: 8877698. DOI: 10.3390/jcm11041093.

A Novel Endothelial Damage Inhibitor Reduces Oxidative Stress and Improves Cellular Integrity in Radial Artery Grafts for Coronary Artery Bypass.

Aschacher T, Baranyi U, Aschacher O, Eichmair E, Messner B, Zimpfer D Front Cardiovasc Med. 2021; 8:736503.

PMID: 34692789 PMC: 8527012. DOI: 10.3389/fcvm.2021.736503.

A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry.

Caliskan E, Sandner S, Misfeld M, Aramendi J, Salzberg S, Choi Y J Cardiothorac Surg. 2019; 14(1):174.

PMID: 31615560 PMC: 6794868. DOI: 10.1186/s13019-019-1010-z.

References

Goldman S, Sethi G, Holman W, Thai H, McFalls E, Ward H . Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. JAMA. 2011; 305(2):167-74. DOI: 10.1001/jama.2010.1976. View

Tsakok M, Montgomery-Taylor S, Tsakok T . Storage of saphenous vein grafts prior to coronary artery bypass grafting: is autologous whole blood more effective than saline in preserving graft function?. Interact Cardiovasc Thorac Surg. 2012; 15(4):720-5. PMC: 3445367. DOI: 10.1093/icvts/ivs275. View

Lau G, Ridley L, Bannon P, Wong L, Trieu J, Brieger D . Lumen loss in the first year in saphenous vein grafts is predominantly a result of negative remodeling of the whole vessel rather than a result of changes in wall thickness. Circulation. 2006; 114(1 Suppl):I435-40. DOI: 10.1161/CIRCULATIONAHA.105.001008. View

Samano N, Geijer H, Liden M, Fremes S, Bodin L, Souza D . The no-touch saphenous vein for coronary artery bypass grafting maintains a patency, after 16 years, comparable to the left internal thoracic artery: A randomized trial. J Thorac Cardiovasc Surg. 2015; 150(4):880-8. DOI: 10.1016/j.jtcvs.2015.07.027. View

Fihn S, Gardin J, Abrams J, Berra K, Blankenship J, Dallas A . 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines,.... Circulation. 2012; 126(25):e354-471. DOI: 10.1161/CIR.0b013e318277d6a0. View

Wilbring M, Tugtekin S, Zatschler B, Ebner A, Reichenspurner H, Matschke K . Even short-time storage in physiological saline solution impairs endothelial vascular function of saphenous vein grafts. Eur J Cardiothorac Surg. 2011; 40(4):811-5. DOI: 10.1016/j.ejcts.2011.01.024. View

Wise E, Hocking K, Eagle S, Absi T, Komalavilas P, Cheung-Flynn J . Preservation solution impacts physiologic function and cellular viability of human saphenous vein graft. Surgery. 2015; 158(2):537-46. PMC: 4492846. DOI: 10.1016/j.surg.2015.03.036. View

Woodward L, Antoniades C, Taggart D . Intraoperative Vein Graft Preservation: What Is the Solution?. Ann Thorac Surg. 2016; 102(5):1736-1746. DOI: 10.1016/j.athoracsur.2016.05.097. View

Wille T, de Groot H, Rauen U . Improvement of the cold storage of blood vessels with a vascular preservation solution. Study in porcine aortic segments. J Vasc Surg. 2008; 47(2):422-31. DOI: 10.1016/j.jvs.2007.09.048. View

10.

de Vries M, Simons K, Jukema J, Braun J, Quax P . Vein graft failure: from pathophysiology to clinical outcomes. Nat Rev Cardiol. 2016; 13(8):451-70. DOI: 10.1038/nrcardio.2016.76. View

11.

Harskamp R, Alexander J, Schulte P, Brophy C, Mack M, Peterson E . Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. JAMA Surg. 2014; 149(8):798-805. PMC: 4332522. DOI: 10.1001/jamasurg.2014.87. View

12.

Souza D, Johansson B, Bojo L, Karlsson R, Geijer H, Filbey D . Harvesting the saphenous vein with surrounding tissue for CABG provides long-term graft patency comparable to the left internal thoracic artery: results of a randomized longitudinal trial. J Thorac Cardiovasc Surg. 2006; 132(2):373-8. DOI: 10.1016/j.jtcvs.2006.04.002. View

13.

Ropers D, Ulzheimer S, Wenkel E, Baum U, Giesler T, Derlien H . Investigation of aortocoronary artery bypass grafts by multislice spiral computed tomography with electrocardiographic-gated image reconstruction. Am J Cardiol. 2001; 88(7):792-5. DOI: 10.1016/s0002-9149(01)01855-0. View

14.

Owens C, Ho K, Conte M . Lower extremity vein graft failure: a translational approach. Vasc Med. 2008; 13(1):63-74. DOI: 10.1177/1358863X07083432. View

15.

Thatte H, Khuri S . The coronary artery bypass conduit: I. Intraoperative endothelial injury and its implication on graft patency. Ann Thorac Surg. 2002; 72(6):S2245-52; discussion S2267-70. DOI: 10.1016/s0003-4975(01)03272-6. View

16.

Alexander J, Hafley G, Harrington R, Peterson E, Ferguson Jr T, Lorenz T . Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005; 294(19):2446-54. DOI: 10.1001/jama.294.19.2446. View

17.

Ugolini P, Pressacco J, LEsperance J, Berry C, LAllier P, Ibrahim R . Evaluation of coronary atheroma by 64-slice multidetector computed tomography: Comparison with intravascular ultrasound and angiography. Can J Cardiol. 2009; 25(11):641-7. PMC: 2776562. DOI: 10.1016/s0828-282x(09)70161-8. View

18.

Weiss D, Juchem G, Kemkes B, Gansera B, Nees S . Extensive deendothelialization and thrombogenicity in routinely prepared vein grafts for coronary bypass operations: facts and remedy. Int J Clin Exp Med. 2009; 2(2):95-113. PMC: 2719701. View

19.

Windecker S, Kolh P, Alfonso F, Collet J, Cremer J, Falk V . 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special.... Eur Heart J. 2014; 35(37):2541-619. DOI: 10.1093/eurheartj/ehu278. View

20.

Thatte H, Biswas K, Najjar S, Birjiniuk V, Crittenden M, Michel T . Multi-photon microscopic evaluation of saphenous vein endothelium and its preservation with a new solution, GALA. Ann Thorac Surg. 2003; 75(4):1145-52; discussion 1152. DOI: 10.1016/s0003-4975(02)04705-7. View